MS Briefs

Pregnancy delays onset of multiple sclerosis symptoms


 

Key clinical point: Pregnancy and childbirth seem to delay the onset of multiple sclerosis by more than 3 years. However, having more pregnancies is not associated with later onset.

Major finding: Onset of clinically isolated syndrome (CIS) was later in women with previous pregnancies and childbirths vs. those without pregnancies and childbirths (hazard ratio, 0.68; P less than .001), with a median delay of 3.3 years. No association was seen between higher number of pregnancies and childbirths and delay in CIS onset.

Study details: The findings are based on a multicenter cohort study of 2,557 women with CIS (mean age at CIS onset, 31.5 years) from the MSBase Registry.

Disclosures: The study was supported by a postgraduate scholarship and Ian Ballard Travel Award from MS Research Australia, an Australian Government Research Training Program Scholarship, and a grant from the National Health and Medical Research Council. The lead author reported receiving grants from MS Research Australia during the conduct of the study; grants, personal fees, and nonfinancial support from Biogen; grants and personal fees from Merck Serono; personal fees from Teva and Novartis; and nonfinancial support from Roche and Genzyme-Sanofi outside the submitted work.

Citation: Nguyen AL et al. JAMA Neurol. 2020 Sep 14. doi: 10.1001/jamaneurol.2020.3324 .

Recommended Reading

Neurodegeneration in MS: Association of cholesterol biomarkers with serum neurofilaments
ICYMI Multiple Sclerosis
ICYMI: MSVirtual2020 Virtual Joint ACTRIMS-ECTRIMS Meeting Summary from MS Resource Center Editor in Chief, Joseph R. Berger, MD
ICYMI Multiple Sclerosis
Neutrophil granulocyte markers may distinguish between demyelinating diseases
ICYMI Multiple Sclerosis
Stressful life events may increase MS risk
ICYMI Multiple Sclerosis
Relapsing-remitting MS: Natalizumab effective on inflammatory phase
ICYMI Multiple Sclerosis
Ofatumumab superior to teriflunomide at lowering relapse rate in MS
ICYMI Multiple Sclerosis
Rituximab vs. glatiramer acetate for secondary progressive multiple sclerosis
ICYMI Multiple Sclerosis
Newer DMTs are more effective than injectable DMTs in pediatric MS
ICYMI Multiple Sclerosis
When Female Patients with MS Ask About Breastfeeding, Here’s What to Tell Them
ICYMI Multiple Sclerosis
NfL blood biomarker captures suboptimal treatment response in MS
ICYMI Multiple Sclerosis